Default Category
-
Imprimis (B)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717496-EEntrepreneurshipThis case is a supplement to Imprimis (Case A). It describes the company's decision to enter into the pharmaceutical compounding business in 2013-14. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients' eyes post-cataract surgery, with the aim of replacing a complex regimen of prescription eye drops. After a successful launch of the compounded medication, Imprimis ran into complica...Starting at €5.74
-
Imprimis (D)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717498-EEntrepreneurshipThis case is a supplement to Imprimis (Case A), Imprimis (Case B), and Imprimis (Case C). It describes Imprimis's 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750/pill. Imprimis also created compounded alternatives to several other branded drugs, and made investments to increase its manufacturing capabilities. The company now ha...Starting at €5.74
-
Elasto Therm: The Next Step
Sharpe, Jim; Weber, JamesCase HBS-813030-EEntrepreneurshipJulia and Nate Burstein were living their dream running their own business and balancing the demands between their work and family obligations while creating a company that was responsive to their employees' and their customers' needs. The Bursteins had joined a large multinational manufacturing company after receiving their MBAs from HBS, but soon left to join Julia's family plastics business. After the business was sold, they struck out on thei...Starting at €8.20
-
Wayne Ferrari: iAutomation at a Crossroads
Sharpe, Jim; Norris, MichaelCase HBS-813120-EEntrepreneurshipWayne Ferrari has bridged the gap between being an independent entrepreneur and a "professional manager." After selling his business to a Private Equity (PE) firm, Ferrari takes on the role of CEO and with their support implements a roll-up strategy to attain growth through acquisition in the mechanical controls distribution industry. Ferrari received support from the PE firm in negotiating and financing acquisitions but faced the challenging tas...Starting at €8.20
-
Wayne Ferrari: iAutomation at a Crossroads, Teaching Note
Sharpe, Jim; Norris, MichaelTeaching Note HBS-813126-EEntrepreneurshipTeaching Note for 813120.Starting at €0.00
-
Elasto Therm: The Next Step, Teaching Note
Sharpe, JimTeaching Note HBS-813132-EEntrepreneurshipTeaching Note for 813030.Starting at €0.00
-
Winnan Metal: Fulfilling the Dream
Kerr, William R.; Sharpe, Jim; Weber, JamesCase HBS-815104-EEntrepreneurshipNeil Kashyap and Neil Lombardo (HBS '08) acquired Winnan Metal, Inc., a metal fabrication shop, after raising a search fund and an 11 month search to fulfill their dreams of becoming business owners. Two weeks after they took control of the company, Winnan's largest customer (60% of company revenues) threatened to take its business elsewhere. One year later, they had regained the respect of their customers and won the trust of their employees to ...Starting at €8.20
-
Imprimis (A)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717426-EEntrepreneurshipThis case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The A case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in 2013. At the time, Imprimis was in the process of seeking FDA approval for a branded drug called Impracor. This process, already difficult, was further complicated by recent manufactur...Starting at €8.20
-
Imprimis (C)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717497-EEntrepreneurshipThis case is a supplement to Imprimis (Case A) and Imprimis (Case B). Set in 2015, it first describes Imprimis's decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the problem of high drug prices in the United States. Recent, drastic price hikes on pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO ...Starting at €5.74
-
Dragonfly Corporation, Teaching Note
Sharpe, Jim; Norris, MichaelTeaching Note HBS-813071-EEntrepreneurshipThis is the teaching note to HBS Case 813042.Starting at €0.00